$GOSS
Gossamer Bio, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Gossamer Bio, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Flagged at $10.25 at 07:37 AM on Nov 11, then ran to $11.94 +16% that session.
The high is the session peak after our first alert, not a realized trade. Not investment advice.
Why is GOSS down today? It is at $11.20 (-2.01%), and our scanner flagged it 61 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment GOSS spikes, and full due diligence on GOSS — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $GOSS 61 times in the last 30 days. Create a free account to track $GOSS, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on GOSS from our scanner (live price and day move above). Our scanner has fired 9 unusual-volume and momentum alerts on GOSS today, peaking at 21.5x its normal volume.
Likely catalystGossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business UpdateReported Gossamer submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2026 for seralutinib for the treatment of PAH. This is the Company’s first NDA submission.Reported The NDA is supported by the Phase 3 PROSERA Study as one adequate and well-controlled clinical investigation, together with confirmatory evidence from the Phase 2 TORREY Study and additional supportive analyses.Reported In August 2026, Gossamer announced a structured private placement with total potential gross proceeds of up to approximately $250 million, including approximately $150 million of committed capital across the initial and second closings., from an SEC filing. Read it →Latest filingS-3Shelf registration (S-3)Nov 16, 2026 · 2 days agoThe company is cleared to issue new shares on demand, but has not yet. Size not stated in the filing.
Some filings did not state a size, so these are floors.
Active shelf on file — the company can issue new shares on demand (valid ~3 years)
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.


The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on GOSS from our scanner (live price and day move above). Our scanner has fired 9 unusual-volume and momentum alerts on GOSS today, peaking at 21.5x its normal volume.
GOSS last traded at $11.20, down 2.01% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
The GOSS Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged GOSS 61 times in the last 30 days.
GOSS (Gossamer Bio, Inc. Common Stock) trades on XNAS, with a market cap of about $70M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge GOSS for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$GOSS discussion
Sign in to ask a question or join the discussion.